BioCentury
ARTICLE | Regulation

Congo, three other countries license Merck’s Ebola vaccine

February 15, 2020 12:44 AM UTC

As biopharmas gear up to develop vaccines and therapies for COVID-19, four African countries at risk from the Ebola outbreak approved and licensed a vaccine from Merck & Co. Friday.

The Democratic Republic of the Congo, Burundi, Ghana and Zambia licensed Ervebo from Merck & Co. Inc. (NYSE:MRK), which allows the pharma to stockpile and distribute the vaccine. Merck said it expects doses of the vaccine to be available in 3Q20...

BCIQ Company Profiles

Merck & Co. Inc.